History {#s0010}
=======

More than 40 antiviral agents are currently available for the treatment of viral infections, including those caused by HIV, hepatitis B virus (HBV), hepatitius C virus (HCV), influenza and the herpesviruses. With increasing developments in molecular biology, a lot of new research are directed towards the design and development of new, specific drugs tailor-made to combat viral infections. Many of the older drugs were discovered incidentally. Dr Bill Prusoff (see [Fig. 1](#f0010){ref-type="fig"} ) discovered the antiviral properties of idoxuridine, a drug active against herpes simplex (HSV), while trying to develop drugs to combat neoplastic disease. In 1977, one of the most useful antiviral drugs, acyclovir, was discovered during a drug development programme not primarily aimed at antiviral therapy. In the early 1980s HIV appeared as a major new viral force to be reckoned with, and in 1985 AZT (azidothymidine) proved to be the first specific inhibitor of the retroviral reverse transcriptase enzyme. Today, antiviral drug research primarily focuses on the design and development of new drugs and the investigation into new retroviral targets that will combat HIV/AIDS, the cause of a global pandemic, and to date still an incurable infection.Fig. 1Prof. Bill Prusoff.(Reproduced with permission from Prof. Prusoff, Yale University.)

Antiviral drugs -- resistance development {#s0030}
=========================================

Stop/ThinkAntivirals -- not all that they seem to be?Although the treatment of viral diseases has come a long way, **obstacles** with regard to the use of antiviral drugs are still encountered. Here are a few:▪Many antiviral agents do not show sufficient selectivity to the viruses that they target. Host cells are also affected by the toxic effects of these drugs (e.g. many antiretrovirals).▪Some viruses have multiple serotypes (e.g. rhinoviruses) or constantly change their antigenic determinants (e.g. influenza virus and HIV). These changes may affect the target molecules of antiviral drugs.▪Many viruses cause latent infections that result in a general decrease in gene expression and expression of drug targets.▪Antiviral drugs are mostly virostatic. Complete inhibition of viral replication seldom occurs. This results in viral persistence and may even give rise to drug resistant mutants!▪Many viruses are impossible or very difficult and impractical to culture (e.g. human papilloma virus, and hepatitis B and C viruses). This complicates experimental studies aimed at the development of new drugs against these viruses.▪Most viral infections are acute and short-lived, with cessation of viral replication and the possibility of drug intervention at the time of diagnosis. (e.g. influenza, hepatitis A).▪Some infections are mild and self-limiting and do not warrant extensive research to develop expensive drugs to treat them with. Good examples include the common cold (caused by rhinoviruses or coronaviruses) and childhood diseases like roseola, parvovirus B19 infection and mumps.

Table 1Agents active against the herpesvirusesDrugStructureTrade nameSpectrum of activityPrincipal indication(s)Route(s) of administration▪ AcyclovirZovirax®HSV-1, HSV-2, VZVMucosal, cutaneous and systemic herpes simplex virus (HSV)-1 and HSV-2 infections (e.g. HSV keratitis, HSV encephalitis, herpes labiales, genital herpes, neonatal herpes)\
Vericellar zoster virus (VZV) infections (incl. herpes zoster)Oral, topical, intravenous▪ ValaciclovirZelitrex®\
Valtrex®As for acyclovirAs for acyclovir\
Prophylaxes for cytomegalovirus (CMV) infections in transplant recipientsOral▪ PenciclovirDenavir®\
Vectavir®As for acyclovirMucocutaneous HSV infections, especially herpes labialisTopical▪ FamciclovirFamvir®As for acyclovirAs for acyclovirOral▪ IdoxuridineHerpid®\
Idoxene®HSV-1, HSV-2, VZVHSV keratitisTopical▪ TrifluridineViroptic®HSV-1, HSV-2, VZVHSV keratitisTopical▪ BrivudinZostex®\
Zonavir®HSV-1 and VZVHSV-1 keratitis and herpes labialis\
VZV infections, especially herpes zosterOral, topical▪ GanciclovirCymevene®\
Cytovene®HSV-1, HSV-2, CMVTreatment and prophylaxis of CMV infections (e.g. CMV retinitis) in immunocompromised/AIDS patients).Oral, intravenous, intraocular/intravitreal implant▪ ValganciclovirValcyte®As for ganciclovirAs for ganciclovirOral▪ FoscarnetFoscavir®HSV-1, HSV-2, VZV, CMV, HIVCMV retinitis in AIDS patients, acyclovir-resistant mucocutaneous HSV and VZV infections in immunocompromised patientsIntravenous infusion▪ CidofovirVistide®\
Forvade®HSV-1, HSV-2, VZV, CMV, HPV, polyomaviruses, adenoviruses, poxvirusesCMV retinitis in AIDS patients acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients\
Recurrent genital herpes, genital warts, laryngeal, cutaneous and cervical HPV lesions\
Molluscum contagiosum and orf lesions\
Adenovirus infections\
PML (progressive multifocal leukoencephalopathy)Intravenous infusion, topical▪ Fomivirsen5'-GCG TTT GCT CTT CTT CTT GCG-3'Vitravene®CMVCMV retinitis in AIDS patientsIntraocular (intravitreal) Table 2Agents active against influenza virusesDrugStructureTrade nameSpectrum of activityPrincipal indication(s)Route(s) of administration▪ AmantadineSymmetral®\
Amantan®Influenza AEarly treatment (within 48 hours) and prophylaxis of influenza A\
Treatment of Parkinson\'s diseaseOral▪ RimantadineFlumadine®Influenza AEarly treatment (within 48 hours) and prophylaxis of influenza AOral▪ ZanamivirRelenza®Influenza A and BEarly treatment (within 48 hours) of influenza A and BInhalation▪ OseltamivirTamiflu®Influenza A and BEarly treatment (within 48 hours) and prophylaxis for influenza A and BOral▪ RibavirinVirazole®\
Virazid®Broad range of DNA and RNA viruses including influenza A and B, respiratory syncytial virus (RSV), hepatitis C virus (HCV), measles, Lassa, Junin, etc.Treatment of RSV in high-risk infants (by aerosol)\
Treatment of HCV in combination with IFN alpha (Rebetron®) or pegylated IFN alphaOral (for treatment of HCV)\
Aerosol (for treatment of RSV)\
Intravenous for treatment of Lassa fever Table 3Agents active against hepatitis BDrugStructureTrade nameSpectrum of activityPrincipal indication(s)Route(s) of administration▪ Human recombinant interferon alphaIntron®Hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human herpesvirus (HHV) 8Treatment of chronic hepatitis B\
Prevention of HBV reactivation in stages of immunosuppression\
Treatment of HCV in combination with ribavirinSubcutaneous\
Intramuscularly\
Intravenous▪ Pegylated interferon alphaPeg-Intron®\
Pegasys®HBV, HCV, HPV, HHV 8As for standard interferon Pegylation allows for slower renal clearance, better tissue distribution and a longer half-life of the drugAs for standard interferon▪ Lamivudine /3TCEpivir®\
Zeffix®HBV, HIV-1 and HIV-2Treatment of chronic hepatitis B\
Treatment of HIV infection. Part of combination therapy, e.g. with AZT (Combivir®), with AZT and ABC (Trizivir®)Oral▪ Adefovir dipivoxilHepsera®HBV, HIV, herpes simplex virus (HSV), cytomegalovirus (CMV)Treatment of drug (lamivudine) resistant chronic HBVOral▪ Emtricitabine /FTCEmtriva®HIV, possibly also HBVTreatment of HIV infections\
Pursued for treatment of HBV infection.Oral▪ EntecavirBaraclude®HBVTreatment of drug (lamivudine) resistant chronic HBVOral Table 4Agents active against picornavirusesDrugStructureTrade nameSpectrum of activityRoute(s) of administration▪ PleconarilPicovir®Picornaviruses (enteroviruses and rhinoviruses)Oral\
Intranasal Table 5Agents active against HIVDrugStructureTrade nameSpectrum of activityPrincipal indication(s)Route(s) of administrationNucleoside reverse transcriptase inhibitors▪ Zidovudine /AZTRetrovir®HIV (types 1 and 2)HIV-1 infection, in combination with other drugs.Oral▪ Didanosine /ddIVidex®As for zidovudine/AZTAs for zidovudine/ AZTOral▪ Zalcitabine /ddCHivid®As for zidovudine/AZTAs for zidovudine/ AZTOral▪ Stavudine/ d4TZerit®As for zidovudine/AZTAs for zidovudine/ AZTOral▪ Lamivudine /3TCEpivir®\
Zeffix®HBV, HIV 1 and 2Treatment of chronic hepatitis B. Treatment of HIV infection. Part of combination therapy, e.g. with AZT (Combivir®), with AZT and ABC (Trizivir®)Oral▪ Abacavir /ABCZiagen®As for zidovudine/AZTAs for zidovudine/AZTOral▪ Emtricitabine /FTCEmtriva®HIV, possibly also hepatitis B virus (HBV)Treatment of HIV infections\
Pursued for treatment of HBV infectionOralNucleotide reverse transcriptase inhibitors▪ Tenofovir disoproxilViread®HIV 1 and 2, HBVHIV-1 infection, in combination with other drugsOralNon-nucleoside reverse transcriptase inhibitors▪ NevirapineViramune®HIV-1HIV-1 infection, in combination with other drugs.Oral▪ DelavirdineRescriptor®HIV-1HIV-1 infection, in combination with other drugs.Oral▪ EfavirenzStocrin®\
Sustiva®HIV-1HIV-1 infection, in combination with other drugs.Oral▪ EtravirineIntelence®HIV-1HIV-1 infection, in combination with other drugs. Usually salvage therapy.OralProtease inhibitors▪ SaquinavirInvirase®HIV-1 and HIV-2HIV-1 infection, in combination with other drugsOral▪ RitonavirNorvir®HIV 1 and 2As for saquinavirOral▪ IndinavirCrixivan®HIV 1 and 2As for saquinavirOral▪ NelfinavirViracept®HIV 1 and 2As for saquinavirOral▪ AmprenavirAgenerase®HIV 1 and 2As for saquinavirOral▪ LopinavirKaletra® (combined with ritonavir)HIV 1 and 2As for saquinavirOral▪ AtazanavirReyataz®HIV 1 and 2As for saquinavirOralCCR5 entry inhibitors▪ MaravirocSelzentry®/Celsentri®HIV-1HIV-1 infection, in combination with other drugs, where the virus uses the CCR5 co-receptorOralMaturation inhibitors▪ Bevirimat--HIV-1In clinical trialsOralIntegrase inhibitors▪ RaltegravirIsentress®HIV-1HIV-1 infection, in combination with other drugsOralViral entry inhibitors▪ Enfuvirtide /T-20YTSLIHSLIEE-SQNQQEKNE-QELLELDKW-ASLWNWFFuzeon®HIV-1HIV-1 infection, in combination with other drugs Usually salvage therapySubcutaneous injection Table 6Antiviral drugs -- resistance developmentVirusResistant drug(s)Mechanism(s) for acquiring resistanceAlternative therapiesHerpes simplex virus (HSV) and varicella zoster virus (VZV) (especially in prolonged treatment of immunocompromised patients)Acyclovir, valacyclovir, pencyclovir, famcyclovirTK (thymidine kinase) mutation(s)Foscarnet\
CidofovirHSV and VZVFoscarnet, cidofovirDNA polymerase mutation(s)Possibly acyclovir, if not multidrug resistantCytomegalovirus (CMV)GancyclovirUL 97 (phosphotransferase) mutation(s)Foscarnet\
CidofovirCMVFoscarnet, cidofovirUL 54/DNA polymerase mutation(s)Possibly gancyclovir, if not multidrug resistantInfluenza AAmantadine, rimantadineMutation(s) in M2 protein channelNeuraminidase inhibitors (zanamivir, oseltamivir), ribavirinHepatitis B virus (HBV)Lamivudine/3TCMutation(s) in the YMDD motif of HBV DNA polymeraseAdefovir dipivoxil, entecavirHIVNucleotide reverse transcriptase inhibitors (NRTIs)↓ Incorporation of NRTI in DNA chain (e.g. M184V mutation that causes high level lamivudine resistance)\
Removal of NRTI from DNA chain (e.g. thymidine analogue mutations that confer resistance against AZT, D4T or tenofovir)Other drug classes, e.g. protease inhibitors (PIs) and/or NNRTIs. In some scenarios, certain NRTIs may still be useful/activeHIVNon-nucleotide reverse transcriptase inhibitors (NNRTIs)Mutations that cause a spacial distortion of the reverse transcriptase enzyme and change the flexibility of the enzyme. This results in ↓ affinity of the hydrophobic pocket for NNRTIs (e.g. K103N and Y181C)Cross-resistance is common amongst the NNRTIs. Other drug classes, e.g. NRTIs and/or PIs may be usefulHIVPIMutation(s) in the catalytic site of the viral protease (e.g. V82A)Cross-resistance is common amongst the PIs. Other drug classes, e.g. NRTIs and/or NNRTIs may be usefulHIVFusion inhibitor (enfuvirtide)gp 41 or gp 120 mutation(s)Other drug classes, e.g. NRTIs and/or NNRTIs and/or PIs may be useful
